Could popular Weight-Loss drugs also fight gum disease?

NCT ID NCT07770906

NEW Not yet recruiting Disease control Sponsor: Cukurova University Source: ClinicalTrials.gov ↗

First seen Aug 18, 2026 · Last updated Aug 18, 2026

Summary

This trial asks whether GLP-1 receptor agonists, a class of drugs used for weight management, can improve gum health and boost the response to standard deep-cleaning treatment in people with obesity and periodontitis. Adults with both conditions will be split into two groups: those who have used a GLP-1 drug for at least three months and those who have not. Everyone receives the same non-surgical periodontal therapy, and researchers compare gum measurements and inflammatory markers before treatment and at three and six months afterward.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GLP-1 receptor agonist (a class of weight-management drugs) combined with non-surgical periodontal therapy (deep cleaning of the gums)
What this could lead to: If GLP-1 drugs help, they could point to a way to improve gum treatment outcomes in people with obesity and periodontitis.
What could go wrong: This is a small, early-stage study. Results may not apply to everyone, and the exact benefits of GLP-1 drugs on gum health remain uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY & OVERWEIGHT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight periodontal disorder periodontitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY & OVERWEIGHT PERIODONTAL DISEASE

More trials for these conditions

Other studies related to the condition(s) this trial covers.